ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 16, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Dec 16, 2010
News
J&J Voluntarily Recalls Rolaids Products
By Patricia Van Arnum
McNeil Consumer Healthcare, a division of McNEIL-PPC, part of Johnson & Johnson (J&J, New Brunswick, NJ) issued a voluntary recall on Dec. 9, 2010, for Rolaid products in the United States and Canada due to reports of possible product contamination.
A Bad Year for Pharmaceutical R&D
By Stephanie Sutton
Figures released by the European Medicines Agency regarding the evaluation of marketing authorization (MA) applications show a significant decline in the number of approved products for 2010.
Abbott, B. Braun, and Roxane Pay $421.2 Million to Settle False-Claims Allegations
By Erik Greb
Abbott Laboratories (Abbott Park, IL), B. Braun Medical (Bethlehem, PA), and Roxane Laboratories, a subsidiary of Boehringer Ingelheim (Ingelheim am Rhein, Germany), agreed to pay the United States $421 million to settle False Claims Act allegations.
Pfizer's Thelin Withdrawn Due to Fatalities
By Stephanie Sutton
Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin from the worldwide market and discontinued all ongoing trials.
Week of Dec. 13, 2010: Company and People Notes: Thermo Fisher to Acquire Dionex; Former SOCMA CEO Joe Acker Dies; and More.
Thermo Fisher to Acquire Dionex; Former SOCMA CEO Joe Acker Dies; and More.
Regulatory Roundup: FDA Issues Final Guidance on How to Comment on Advisory Committee Meetings
FDA Issues Final Guidance on How to Comment on Advisory Committee Meetings

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here